Statin dose reduction with complementary diet therapy: A pilot study of personalized medicine

Autor(es)

Scolaro, Bianca ^[1] ; Nogueira, Marina S. ^[1] ; Paiva, Aline ^[1] ; Bertolami, Adriana ^[2] ; Barroso, Lucia P. ^[3] ; Vaisar, Tomas ^[4] ; Heffron, Sean P. ^[5] ; Fisher, Edward A. ^[5] ; Castro, Inar A. ^{[1, 5]}

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Dept Food & Expt Nutr, Fac Pharmaceut Sci, Av Lineu Prestes 580, B14, BR-05508900 Sao Paulo - Brazil

^[2] Dante Pazzanese Inst Cardiol, Dyslipidemia Med Sect, Av Dr Dante Pazzanese 500, BR-04012909 Sao Paulo - Brazil

^[3] Univ Sao Paulo, Inst Math & Stat, Dept Stat, Rua Matao 1010, BR-05508090 Sao Paulo - Brazil

^[4] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 - USA

^[5] NYU, Sch Med, Dept Med, Leon H Charney Div Cardiol, New York, NY 10016 - USA

• Tipo de documento: Artigo Científico
• Fonte: MOLECULAR METABOLISM; v. 11, p. 137-144, MAY 2018.
• Citações Web of Science: 2

Resumo

Objective: Statin intolerance, whether real or perceived, is a growing issue in clinical practice. Our aim was to evaluate the effects of reduced-dose statin therapy complemented with nutraceuticals. Methods: First phase: Initially, 53 type 2 diabetic statin-treated patients received a supplementation with fish oil (1.7 g EPA + DHA/day), chocolate containing plant sterols (2.2 g/day), and green tea (two sachets/day) for 6 weeks. Second phase: ``Good responders{''} to supplementation were identified after multivariate analysis (n = 10), and recruited for a pilot protocol of statin dose reduction. ``Good responders{''} were then provided with supplementation for 12 weeks: standard statin therapy was kept during the first 6 weeks and reduced by 50% from weeks 6-12. Results: First phase: After 6 weeks of supplementation, plasma LDL-C (-13.7% +/- 3.7, P = .002) and C- reactive protein (-35.5% +/- 5.9, P = .03) were reduced. Analysis of lathosterol and campesterol in plasma suggested that intensity of LDL-C reduction was influenced by cholesterol absorption rate rather than its synthesis. Second phase: no difference was observed for plasma lipids, inflammation, cholesterol efflux capacity, or HDL particles after statin dose reduction when compared to standard therapy. Conclusions: Although limited by the small sample size, our study demonstrates the potential for a new therapeutic approach combining lower statin dose and specific dietary compounds. Further studies should elucidate ``good responders{''} profile as a tool for personalized medicine. This may be particularly helpful in the many patients with or at risk for CVD who cannot tolerate high dose statin therapy. (C) 2018 The Authors. Published by Elsevier GmbH. (AU)

• Processo FAPESP: 15/16243-5 - Abordagem combinada de compostos bioativos sobre biomarcadores de risco para aterosclerose: Parte II
• Beneficiário: Inar Castro Erger
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 14/04247-3 - Abordagem combinada de compostos bioativos sobre biomarcadores de risco para aterosclerose
• Beneficiário: Bianca Scolaro
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 15/18859-3 - Efeitos da suplementação combinada de compostos bioativos sobre funcionalidade da HDL em pacientes tratados com estatinas
• Beneficiário: Bianca Scolaro
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Doutorado
• Processo FAPESP: 14/18576-9 - Abordagem combinada de compostos bioativos sobre biomarcadores de risco para aterosclerose
• Beneficiário: Aline Tomaz de Paiva
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica